- Programs & Services
- Cost Management
- Specialty Management
- Care Management
- Member Engagement
- Health Plan Client Engagement
The latest gene therapy pipeline update shows how there are a growing number of these innovative treatments in development for a range of conditions. In 2021 alone, multiple chimeric antigen receptor (CAR) T-cell therapies for various cancers, including two for multiple myeloma, are expected to be approved.
Our periodic gene therapy pipeline update report shares information about treatments that may come up for review and approval by the U.S. Food and Drug Administration (FDA) in the near-term.
In 2022, we also expect to see additional gene therapies for hemophilia – a condition that has no cure and requires lifelong factor replacement treatment.
The information contained herein is compiled from independent clinical sources and is provided for informational purposes only. Due to circumstances beyond CVS Health’s control, prospective drug launch dates are subject to change without notice. This information should not be solely relied upon for decision-making purposes. This document includes products that may fall under a general specialty drug benefit. All products contained herein may not be provided by CVS Specialty.
This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health.
Source: RxPipeline, CVS Health Clinical Affairs. Information current as of November 5, 2020.
©2020 CVS Health and/or one of its affiliates.